Idogen’s first trading day on Nasdaq First North noted at Times Square in New York
Idogen AB (“Idogen”) announced that as of today, the company’s share is being traded on Nasdaq First North Growth Market. The traditional ringing of the bell was skipped owing to the prevailing COVID-19 pandemic, but the event was noted on the Nasdaq trading floor at Times Square in New York. Idogen is developing completely new types of cell therapies that have the potential to improve the treatment of hemophilia A and reduce the risk of transplanted kidneys being rejected.
The listing on Nasdaq First North Growth Market is a natural step in Idogen’s development. Over the past year, the company has made significant advances in its unique cell therapy projects. A new combination of substances to produce tolerogenic dendritic cells has been established and a patent application has been submitted, with potential market exclusivity until 2040. In addition, a partnership has been initiated with Radboud University Medical Center in the Netherlands to establish a scalable manufacturing process that meets the requirements of Good Manufacturing Practice (GMP) prior to the start of clinical trials.
During the current year, Idogen is planning to file an application for clinical testing of IDO 8, which is being developed to re-induce tolerance in patients with hemophilia A who are resistant to the standard factor VIII treatment. Clinical tests are expected to begin in the first half of 2021. The IDO T drug project is being developed for the purpose of reducing the risk of transplanted kidneys being rejected, and preclinical evaluations will continue through 2020. Following that, preparations will be made for the first clinical trial, which is expected to begin in 2022.
“The listing on Nasdaq First Growth Market is an external validation of the quality of Idogen’s corporate governance, internal procedures and financial information, and increases the Company’s visibility on the capital market. Through this, we hope to attract even more long-term owners who see the potential in our unique cell therapy projects,” says Idogen CEO Anders Karlsson.
Trading of Idogen’s share will continue under ISIN code SE0014428561 and symbol IDOGEN. The company’s shareholders will not need to take any action in conjunction with the change of listing.
The company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm; tel: +46 (0)8-463 80 00, e-mail: email@example.com.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Tel: +46 70 918 00 10
The information was submitted for publication, through the agency of the contact persons set out above, on June 4, 2020.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.